Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target

BACKGROUND: Cisplatin-based chemotherapy is currently part of the standard of care for bladder cancer (BC). Unfortunately, some patients respond poorly to chemotherapy and have acquired or developed resistance. The molecular mechanisms underlying this resistance remain unclear. Here, we introduce a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Lett
Main Authors: Jung, Jae Hun, You, Sungyong, Oh, Jae Won, Yoon, Junhee, Yeon, Austin, Shahid, Muhammad, Cho, Eunho, Sairam, Vikram, Park, Taeeun D., Kim, Kwang Pyo, Kim, Jayoung
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6181132/
https://ncbi.nlm.nih.gov/pubmed/30145203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2018.08.014
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares